ABSTRACT

Extensive studies have shown that breast milk is the best source of nutrition for infants, especially during the first six months, because it fulfills almost all of their nutritional needs. Among the many functional building blocks in breast milk, human milk oligosaccharides (HMOs) have been receiving more attention recently. Furthermore, it is the third most common group of compounds in human milk, and studies have demonstrated the health benefits it provides for infants, including improved nutritional status. HMOs were previously known as the ‘bifidus factor’ due to their ‘bifidogenic’ or prebiotic effects, which enabled the nourishment of the gastrointestinal microbiota. Healthy gastrointestinal microbiota are intestinal health substrates that increase nutrient absorption and reduce the incidence of diarrhea. In addition, HMOs, directly and indirectly, protect infants against infections and strengthen their immune system, leading to a positive energy balance and promoting normal growth. Non-modifiable factors, such as genetics, and modifiable factors (e.g., maternal health, diet, nutritional status, environment) can influence the HMO profile. This review provides an overview of the current understanding of how HMOs can contribute to the prevention and treatment of nutritional issues during exclusive breastfeeding.

Keywords: Human milk; Oligosaccharides; Breast feeding; Nutritional status

INTRODUCTION

For infants up to six months of age, the best nutrition is exclusive breastfeeding. This practice is recommended by the World Health Organization (WHO) for up to one to two years [1]. Breastfeeding protects the infants against infections and malocclusion, increases intelligence, and reduces the risk of being overweight and diabetes [2]. According to the WHO, the overall rate of exclusive breastfeeding for infants under six months of age is only 40% [3].
Human breast milk contains macronutrients, micronutrients, digestive enzymes, hormones, immune cells, and many bioactive molecules. Human milk oligosaccharides (HMOs) are the third most abundant group of bioactive substrates in breast milk, following lactose (70 g/L) and lipids (40 g/L) [4]. This means that approximately 100 HMOs are fully characterized; therefore, it is assumed that more than 200 HMOs exist [5]. Oligosaccharides are only found in trace amounts in the mature milk of animals [6].

The quantity, quality, and balance in intestinal microbiota are essential to an infant’s health and directly and indirectly affect nutritional status [7]. The disruption of the composition and function of the gut microbiome influence the nutritional status of infants, leading to undernutrition and obesity [8]. Wasting, stunting, and obesity in infants are associated with dysbiosis [9]. Originally, HMOs were identified as the ‘bifidus factor’ in breast milk with their ‘bifidogenic’ or prebiotic effects [4]. The presence of HMOs determines the development of the infant’s gastrointestinal (GI) microbiota [10].

Genetic profile influences the HMO profile [4]; the α-1-2-fucosyltransferase (FUT-2) and α-1-3-4-fucosyltransferase (FUT-3) genes, in particular, specify the HMO profile. Furthermore, FUT-2 is responsible for the Se gene and categorizes mothers as secretors (Se+) or non-secretors (Se–), while the FUT-3 gene is responsible for the Lewis Group gene and categorizes mothers as Lewis+ or Lewis– [4]. Higher concentrations and more complex profiles of HMOs are found in Se+ Le+ mothers than in Se– Le– mothers [11]. The secretor status is influenced by geographic and racial differences, and almost 20% of the population is estimated to be composed of non-secretors [12].

This review explores how HMOs can contribute to the prevention and treatment of nutritional issues during exclusive breastfeeding.

### HUMAN MILK OLIGOSACCHARIDES

The structure of HMOs consist of 3 to 14 monosaccharides [13]. Specifically, D-glucose (Glc), D-galactose, N-acetylgalactosamine (GlcNAc), L-fucose, and sialic acid (Sia; N-acetyl neuraminic acid) are the five monosaccharide building blocks of HMOs [14]. There are three classifications of HMOs [7]; (a) 35-50% of the HMOs are neutral (fucosylated) HMOs (e.g., 2′FL, 3′FL, lacto-N-fucopentaose (LNFP) I, LNFP II, and LNFP III) and contain fucose at the terminal position; (b) 42-55% are nitrogen-containing neutral (non-fucosylated) and contain GlcNAc at the terminal position (e.g., lacto-N-neotetraose [LNnT] and lacto-N-tetraose [LNT]); and (c) the remaining 12-14% are acidic (sialylated; e.g., 3′SL and 6′SL) and contain Sia at the terminal position. The type, structure, and size of the HMOs are listed in Table 1 [15].

The basic blueprints of HMO synthesis are generally applicable to all HMOs, although inter-and intra-personal alterations affect the variations [16]. These factors are further categorized into modifiable and non-modifiable factors. Genetic factors are non-modifiable factors determined by the FUT-2 and FUT-3 genes. The maternal secretor status has a more significant influence on HMO variations than does the Lewis blood type status, as described in Table 2 [17,18]. However, only 60% of Asian mothers are secretors, compared to 74% of Caucasian mothers who are secretors [12]. The modifiable factors include maternal health and nutritional status, diet [19], duration of pregnancy [4], course of lactation [12], duration of breastfeeding [12], infant-related factors (e.g., sex, birth weight) [12], and the environment [11].
Table 1. Highly abundant HMOs in human breast milk

| Oligosaccharide (abbreviation) | Structure | Type and size |
|-------------------------------|-----------|---------------|
| 2'-fucosyllactose (2'-FL)     | Fucα1, 3 Galβ1, 4 Glc | Fucosylated, neutral, triose |
| Lacto-N-fucopentaose I (LNFP I) | Fucα1, 3 (Galβ1, 3 GlcNAcβ1, 3 Galβ1, 4 Glc | Fucosylated, neutral, tetraose |
| Lacto-N-fucopentaose I (LNDFH I) | Fucα1, 3 (Fucα1, 3 Galβ1, 3 GlcNAcβ1, 3 Galβ1, 4 Glc | Difucosylated, neutral, hexaose |
| Lacto-N-fucopentaose II (LNFP II) | Galβ1, 4 (Fucα1, 3 GlcNAcβ1, 3 Galβ1, 4 Glc | Fucosylated, neutral, pentose |
| 3'-fucosyllactose (3-FL)      | Galβ1, 4 (Fucα1, 3 Glc) | Fucosylated, neutral, triose |
| Lactodifucotetraose (LDFT)    | Fucα1, 3 Galβ1, 4 (Fucα1, 3 Glc) | Difucosylated, neutral, tetraose |
| Disialyllacto-N-tetraose (DSLNT) | NeuSAcβ1, 3 (Galβ1, 4 (NeuSAcβ1, 3 GlcNAcβ1, 3 Galβ1, 4 Glc | Difucosylated, acidic, hexaose |
| 3'-sialyl lactose (3'-SL)     | NeuSAcβ1, 3 Galβ1, 4 Glc | Sialyl, acidic, triose |
| 6'-sialyl lactose (6'-SL)     | NeuSAcβ1, 3 Galβ1, 4 Glc | Sialylated, acidic, triose |
| Monofucosylmonosialyllacto-N-hexaose (MFMSLH) | NeuSAcβ1, 3 (Galβ1, 4 (NeuSAcβ1, 3 GlcNAcβ1, 3 Galβ1, 4 Glc | Sialylated and fuselcosylated, acidic, octaose |
| Lacto-N-tetraose (LNT)        | Galβ1, 4 (GlcNAcβ1, 3 Galβ1, 4 Glc) | Nonfucosylated, neutral, tetraose |
| Lacto-N-neotetraose (LNNT)    | Galβ1, 4 (GlcNAcβ1, 3 Galβ1, 4 Glc) | Nonfucosylated, neutral, tetraose |

Glc: D-glucose, Gal: D-galactose, GlcNAc: N-acetylglucosamine, Fuc: L-fucose, Neu5Ac: N-acetyl neuraminic acid.
Adapted from Gastroenterology and Nutrition: Neonatology Questions and Controversies. 3rd ed. Philadelphia: Elsevier Saunders, 2019:43-58 [15].

Table 2. Milk oligosaccharide groups and the related genotypes

| Milk group   | Genotypes | Phenotypes | Fucosyl-Oligosaccharides* |
|--------------|-----------|------------|----------------------------|
| Secretor     | Lewis     | Secretor   | Lewis positive             |
| 1            | Se/-      | Le/-       | 2'-FL, LNDFH I-II, LNFP I-II+III, 3FL, LDFT, LNN, LTN, LNH, MFLNH II |
| 2            | se/se     | le/le      | Non-secretor Lewis positive |
| 3            | se/se     | le/le      | Lewis negative             |
| 4            | se/se     | le/le      | Non-secretor Lewis negative |

2'-FL: 2'-fucosyllactose, LNDFH: lacto-N-difucohexose, LNFP: lacto-N-fucopentaose, 3FL: 3'-fucosyllactose, LDFT: lactofucoditetraose, LNN: lacto-N-neotetraose, LNT: lacto-N-tetraose, LNH: lacto-N-hexaose, MFLNH: monofucosylacto-N-hexaose, DSLNT: disialyllacto-N-tetraose, LST: sialyllacto-N-tetraose, 3'SL: 3'-sialyl lactose, 6'SL: 6'-sialyl lactose.
*All sialyl-oligosaccharides, including DSLNT, LST, 3'SL, and 6'SL, are present in all milk groups.
Adapted from Bering (Nutrients 2018;10:1461) [18].

HMO biosynthesis is an extension of lactose biosynthesis, as all HMOs carry lactose at their reducing ends. This occurs in the Golgi apparatus of cells lining the alveoli and smaller ductules and begins with Glc [20]. Most of the effects of HMOs occur on cells in lymphoid tissues associated with mucous membranes because of the natural resistance of these cells to GI and duodenal digestion. These effects can also transit through the GI tract [21]. HMOs can also perform at the systemic level since approximately 1% of HMOs are absorbed and enter the systemic circulation [7].

ADVANTAGES OF HMOs

Maintenance of gut health

The proposed theories of how HMOs help combat malnutrition are based on the modulation of the gut microbiome [22]. The quantity and quality of the gut microbiome are related to malnutrition and obesity in infants [23]. The composition of the neonatal gut microbiota is known to be associated with HMOs [24]. The bifidogenic and prebiotic effects of HMOs promote the sustenance of the microbiome in infants [4].

Although the mechanisms are not clear, it is stipulated that the microbiome regulates the somatotrophic axis, growth hormone, and insulin-like growth factor-1 activity to stimulate infant growth [23]. HMOs also influence appetite-regulating hormones, including ghrelin, glucagon-like peptide-1, and leptin [8]. Moreover, the microbiome influences metabolism and the nutritional status by affecting digestion, absorption, and energy storage [23].

https://doi.org/10.5223/pghn.2021.24.6.501
Abnormalities and immaturity of the microbiome disrupt the intestinal barrier, resulting in the deterioration and dullness of mucus, intestinal permeability, and immune dysfunction, affecting the health and growth of infants [23]. The essential amino acids, one of the vital nutrients for normal growth, are also influenced by microbiome dysbiosis [23]. Recent studies found that the normal composition pattern of the microbiota in the malnourished infants they examined was disrupted, suggesting that disrupted microbiota development impairs healthy postnatal growth [24].

**Protection against infection**

Infants are more vulnerable to infection by opportunistic pathogens because of their immature intestinal immune system [25]. To achieve good nutritional status, an infant must receive optimal energy intake; however, infections can negatively affect nutritional status. Frequent infection in infants causes deficits in calories, resulting in a negative energy balance, failure in weight gain, and eventually impaired linear growth [26].

The first line of defense against innate immunity is intestinal health and intestinal barrier function. Several mechanisms have been suggested for the anti-infection property of HMOs, mainly in that they (i) are believed to be the preferred substrate for the growth of certain “good” bacteria in the GI tract; (ii) prevent bacterial binding by acting as decoy molecules bound by pathogenic bacteria; and (iii) modulate the immune system through direct interaction [27].

Alkaline phosphatase is an important molecule for the maintenance of gut barrier function. The increased expression of alkaline phosphatase indicates the differentiation and growth of human intestinal epithelial cells, and alkaline phosphatase is known to be promoted by sialyllactose [28]. Relatively high amounts of LNFP I and III and relatively low amounts of LNT are found in breast milk received by infants without sick days (e.g., diarrhea, fever, rash, coughing). The increased LNFP 1 levels are believed to help infants fight infection and maintain normal growth [29]. The incidence of diarrhea after two years is reduced by a relatively high abundance of fucosyl oligosaccharides. A high concentration of LNFP II in uninfected infants exposed to human immunodeficiency virus (HIV) results in a decrease in gastroenteritis and respiratory infections after 6 and 12 weeks, which also reduces the risk of HIV transmission and mortality [30].

Few studies have demonstrated the role of HMOs in respiratory viral infections. The viral load of the respiratory syncytial virus (RSV) has been shown to decrease in the presence of 2′FL, while the influenza viral load decreases due to the action of LNnT and 6′SL. Sialylated HMOs, 3′SL, and 6′SL, can block the hemagglutinin of the influenza virus, thereby preventing influenza virus infection [31]. Subsequently, other additional Sia-containing HMOs have been identified to bind the influenza virus. The influenza viral load in airway epithelial cells has been shown to decrease in the presence of 6′SL and LNnT, while 2-FL influences RSV infection [32]. Infants have been found to experience mild respiratory and enteric problems by 6 and 12 weeks, which were observed to be associated with LNFI levels in breast milk and infant feces at two weeks postpartum [33]. The theory for this mechanism is still unknown. It is believed that absorbed HMOs enter the bloodstream and airways to protect infants against pathogens. Milk reflux coats the mucosal respiratory airways with oligosaccharides [34].
**Boosting of the immune system**

The shifting of T cell responses to balanced Th1/Th2 cytokine production is the method used by HMOs to alter the immune response [35]. The Th17, Th22, and γδ T cells play an important role in the production of interleukin (IL)-22. This complex maintains the integrity of the epithelial barrier and regulates the composition of the microbiota [36]. The anti-inflammatory activity of 3'SL works by reducing the expression of IL-12 and IL-8 in Caco-2 cells while being mediated by nuclear factor kappa-light-chain-enhancer of activated B cells and stimulates the anti-inflammatory nuclear receptor peroxisome proliferator activated receptor gamma [37]. A study on *in vitro* inflammatory models showed the anti-inflammatory effects of neutral HMOs on the intestinal epithelium [38]. These effects were later studied in an infant receiving infant formula supplemented with 2'FL by measuring inflammatory cytokines in the infant’s systemic circulation [39]. This study revealed lower levels of Tumour necrosis factor α, IL-1α, IL-1β, and IL-6 resembling 2’FL found in breastfed infants. Previous studies on LNFP III and LNnT also demonstrated their immunosuppressive effects [40], and LNFP III was found to induce IL-10 production in macrophages [41].

**Infant growth**

Infant growth is not related to the maternal secretor and Lewis group statuses [42]. However, the contents of HMOs that are influenced by the maternal secretor status (2’-FL and LNFP I) has been associated with infant growth and anthropometry. Specific HMOs found in secretor mothers, such as 2’-FL and LNFP I, have been associated with infant growth. This increases the consideration of supplementing infant formulas with 2’FL and LNnT as a part of infant nutrition [43].

A previous study found that the concentration of total HMOs in the colostrum was not particularly high and was associated more with the blood characteristics of the mother. High amounts of 1,2 fucosylated HMOs were found in secretor mothers, while only non-detectable or very low concentrations were found in non-secretor mothers [44]. These differences have biological consequences for infants. The incidence of diarrhea caused by the enterotoxigenic *Escherichia coli*, *Campylobacter jejuni*, or caliciviruses was significantly reduced in the presence of 1,2 fucosylated HMOs [45]. Furthermore, a low level of FUT-2 oligosaccharides reduced the diversity, richness, and abundance of Bifidobacterium. Although the secretory enzymes transferring 1,2-fucose were low, 1,3- and 1,4-fucosylated HMOs and the non-fucosylated residue were detected at high levels in the milk of non-secretor mothers [46]. Sprenger et al. [42] defined the level of 2’FL as a marker of secretor status correlated with a lower incidence of eczema and allergies mediated by immunoglobulin E.

In a group of Gambian infants, 3SL was positively correlated with the weight-for-age Z-score (WAZ). The higher production of 3’S from 4 to 20 weeks was associated with a higher WAZ score of the infant at 20 weeks. In contrast, the same study showed a negative association between sialyllacto-N-neotetraose and WAZ scores [47].

A weight velocity at zero to five months of age and a fat mass index (FMI) at five months of age were positively associated with 2’-FL. Conversely, a negative association was found between height-for-age Z-scores (*p*=0.008), weight velocity at zero to five months of age (*p*=0.009), and FMI (*p*=0.033) with LNnT. In other words, a lower LNnT can lead to a high weight gain (HW group) (*p*=0.012). Certain HMOs, including 2’FL added to infant formula, are suspected to be the cause of excessive weight gain [48].

https://doi.org/10.5223/pghn.2021.24.6.501
Severely stunted infants at six months in the Malawian group previously received milk from mothers that produced significantly less sialylated HMOs than that of mothers with healthy infants. This showed a positive association between growth and sialylated HMOs. This finding was supported by another Malawian group that showed a significantly low level of total and sialylated HMO content in stunted infants [49]. At six months, each 1-mg/mL increase in disialyllacto-N-tetraose was associated with a 0.01 cm increase in the six-months length ($\beta=0.01$, $p=0.04$) [50].

In contrast, in a follow-up study of infants up to four months of age, there were no significant differences in body weight, body length, body mass index (BMI), and head circumference between infants receiving low or high FUT-2 associated HMOs. Although the data did not show a statistically significant result, male infants receiving milk with low 2'-FL were likely to have a slightly higher BMI at one month, though this was no longer observed after four months when they had a lower BMI and body weight gain [42].

**CONCLUSION**

HMOs play a crucial role in infants' nutritional status. Until recently, only a few studies carried out on humans have examined the association between HMOs and the nutritional status of infants, some of which possibly only had a small study population and limited study period. The results of these studies were also contradictory due to mixed interpretations. More data from large and longitudinal studies are needed to clarify the functions of HMOs.

**REFERENCES**

1. Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012;129:e827-41.
2. Victora CG, Bahl R, Barros AI, França GV, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet 2016;387:475-90.
3. UNICEF, World Health Organization. Global Breastfeeding Scorecard, 2017. Tracking progress for breastfeeding policies and programmes [Internet]. New York (NY), Geneva: UNICEF, World Health Organization; 2017 [cited 2021 Jul 24]. Available from: https://apps.who.int/nutrition/publications/infantfeeding/global-bf-scorecard-2017.pdf?ua=1.
4. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 2012;22:1147-62.
5. Urashima T, Asakuma S, Leo F, Fukuda K, Messer M, Oftedal OT. The predominance of type I oligosaccharides is a feature specific to human breast milk. Adv Nutr 2012;3:473S-82S.
6. Lane JA, Mehra RK, Carrington SD, Hickey RM. The food glycome: a source of protection against pathogen colonization in the gastrointestinal tract. Int J Food Microbiol 2010;142:1-13.
7. Bode L. The functional biology of human milk oligosaccharides. Early Hum Dev 2015;91:619-22.
8. Pekmez CT, Dragsted LO, Brahe LK. Gut microbiota alterations and dietary modulation in childhood malnutrition - the role of short chain fatty acids. Clin Nutr 2019;38:615-30.
9. Gough EK, Stephens DA, Moodie EE, Prendergast AJ, Stoltzfus RJ, Humphrey JH, et al. Linear growth faltering in infants is associated with Acidaminococcus sp. and community-level changes in the gut microbiota. Microbiome 2015;3:24.

https://doi.org/10.5223/pghn.2021.24.6.501
10. Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 2015;3:13.

11. McGuire MK, Meehan CL, McGuire MA, Williams JE, Foster J, Sellen DW, et al. What’s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. Am J Clin Nutr 2017;105:1086-100.

12. Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, et al. Human milk oligosaccharide concentrations are associated with multiple fixed and modifiable maternal characteristics, environmental factors, and feeding practices. J Nutr 2018;148:1733-42.

13. Wu S, Tao N, German JB, Grimm R, Lebrilla CB. Development of an annotated library of neutral human milk oligosaccharides. J Proteome Res 2010;9:4138-51.

14. Jovanović M, Tyldesley-Worster R, Pohlentz G, Peter-Katalinić J. MALDI Q-TOF CID MS for diagnostic ion screening of human milk oligosaccharide samples. Int J Mol Sci 2014;15:6527-43.

15. Morrow AL, Newburg DS. Human milk oligosaccharides. In: Neu J, Poin Dexter B, Polin RA, eds. Gastroenterology and nutrition: neonatology questions and controversies. 3rd ed. Philadelphia: Elsevier, 2019:43-58.

16. Bode L, Jantscher-Krenn E. Structure-function relationships of human milk oligosaccharides. Adv Nutr 2012;3:383S-91S.

17. Totten SM, Ziskovic AM, Wu S, Nguyen U, Freeman SL, Ruhaak LR, et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res 2012;11:6124-33.

18. Bering SB. Human milk oligosaccharides to prevent gut dysfunction and necrotizing enterocolitis in preterm neonates. Nutrients 2018;10:1461.

19. Meyer KM, Mohammad M, Bode L, Chu DM, Ma J, Haymond M, et al. Maternal diet structures the breast milk microbiome in association with human milk oligosaccharides and gut-associated bacteria. Am J Obstet Gynecol 2017;216(1 Suppl):S15.

20. Bode L. Human milk oligosaccharides: prebiotics and beyond. Nutr Rev 2009;67 Suppl 2:S183-91.

21. Garrido D, Dallas DC, Mills DA. Consumption of human milk glycoconjugates by infant-associated bifidobacteria: mechanisms and implications. Microbiology (Reading) 2013;159(Pt 4):649-64.

22. Le Doare K, Holder B, Bassett A, Pannaraj PS. Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity. Front Immunol 2018;9:361.

23. Robertson RC, Manges AR, Finlay BB, Prendergast AL. The human microbiome and child growth - first 1000 days and beyond. Trends Microbiol 2019;27:131-47.

24. Wang M, Li M, Wu S, Lebrilla CB, Chapkin RS, Ivanov I, et al. Fecal microbiota composition of breastfed infants is correlated with human milk oligosaccharides consumed. J Pediatr Gastroenterol Nutr 2015;60:825-33.

25. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Curr Opin Microbiol 2020;56:30-7.

26. Schmidt WP, Genser B, Luby SP, Chalabi Z. Estimating the effect of recurrent infectious diseases on nutritional status: sampling frequency, sample-size, and bias. J Health Popul Nutr 2011;29:317-26.

27. Austin S, De Castro CA, Bénet T, Hou Y, Sun H, Thakkar SK, et al. Temporal change of the content of 10 oligosaccharides in the milk of Chinese urban mothers. Nutrients 2016;8:346.

28. Kuntz S, Rudloff S, Kunz C. Oligosaccharides from human milk influence growth-related characteristics of intestinally transformed and non-transformed intestinal cells. Br J Nutr 2008;99:462-71.
29. Davis EC, Wang M, Donovan SM. The role of early life nutrition in the establishment of gastrointestinal microbial composition and function. Gut Microbes 2017;8:143-71.

30. Doherty AM, Lodge CJ, Dharmage SC, Dai X, Bode L, Lowe AJ. Human milk oligosaccharides and associations with immune-mediated disease and infection in childhood: a systematic review. Front Pediatr 2018;6:91.

31. Zevgiti S, Zabala JG, Darji A, Dietrich U, Panou-Pomonis E, Sakarellos-Daiatsiotis M. Sialic acid and sialyl-lactose glyco-conjugates: design, synthesis and binding assays to lectins and swine influenza H1N1 virus. J Pept Sci 2012;18:52-8.

32. Duska-McEwen G, Senft AP, Ruetschilling TL, Barrett EG, Buck RH. Human milk oligosaccharides enhance innate immunity to respiratory syncytial virus and influenza in vitro. Food Nutr Sci 2014;5:1387-98.

33. Stepans MB, Wilhelm SL, Hertzog M, Rodehorst TK, Blaney S, Clemens B, et al. Early consumption of human milk oligosaccharides is inversely related to subsequent risk of respiratory and enteric disease in infants. Breastfeed Med 2006;1:207-15.

34. Heacock HJ, Jeffery HE, Baker JL, Page M. Influence of breast versus formula milk on physiological gastroesophageal reflux in healthy, newborn infants. J Pediatr Gastroenterol Nutr 1992;14:41-6.

35. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, et al. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr Allergy Immunol 2010;21:1179-88.

36. Prendergast AJ, Kelly P. Interactions between intestinal pathogens, enteropathy and malnutrition in developing countries. Curr Opin Infect Dis 2016;29:229-36.

37. Zenhom M, Hyder A, de Vrese M, Heller KJ, Roeder T, Schrezenmeir J. Prebiotic oligosaccharides reduce proinflammatory cytokines in intestinal Caco-2 cells via activation of PPARγ and peptidoglycan recognition protein 3. J Nutr 2011;141:971-7.

38. Ring RC, Hold MM, Vennetti DC, Bell J, Dunlop J, Mengeling MW, et al. The human milk oligosaccharide 2′-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut 2016;65:33-46.

39. Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. Similar to those who are breastfed, infants fed a formula containing 2′-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial. J Nutr 2016;146:2559-66.

40. Atoschin O, Da’dara AA, Walker M, Harn DA. The immunomodulatory glycan LNPfpiii initiates alternative activation of murine macrophages in vivo. Immunology 2008;125:111-21.

41. Atoschin O, Harn D, LNPfpiii/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin Diag Lab Immunol 2005;12:1041-9.

42. Sprenger N, Odenwald H, Kukkonen AK, Kuitunen M, Savilahti E, Kunz C. FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk. Eur J Nutr 2017;56:1293-301.

43. Hegar B, Wilbowo Y, Basrowi RW, Ranuh RG, Sudarno SM, Munasir Z, et al. The role of two human milk oligosaccharides, 2′-fucosyllactose and lacto-N-neotetraose, in infant nutrition. Pediatr Gastroenterol Hepatol Nutr 2019;22:330-40.

44. Gabrielli O, Zampini L, Galeazzi T, Padella L, Santoro L, Peila C, et al. Preterm milk oligosaccharides during the first month of lactation. Pediatrics 2011;128:e1520-31.

45. Newburg DS, Ruiz-Palacios GM, Altaye M, Chaturvedi P, Meinzen-Derr J, Guerrero Mde L, et al. Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants. Glycobiology 2004;14:253-63.
46. Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res 2015;77:229-35.

47. Davis JC, Lewis ZT, Krishnan S, Bernstein RM, Moore SE, Prentice AM, et al. Growth and morbidity of Gambian infants are influenced by maternal milk oligosaccharides and infant gut microbiota. Sci Rep 2017;7:40466.

48. Larsson MW, Lind MV, Laursen RP, Yonemitsu C, Larnkjær A, Mølgaard C, et al. Human milk oligosaccharide composition is associated with excessive weight gain during exclusive breastfeeding—an explorative study. Front Pediatr 2019;7:297.

49. Charbonneau MR, O'Donnell D, Blanton LV, Totten SM, Davis JC, Barratt MJ, et al. Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 2016;164:859-71.

50. Alderete TL, Autran C, Brekke BE, Knight R, Bode L, Goran MI, et al. Associations between human milk oligosaccharides and infant body composition in the first 6 mo of life. Am J Clin Nutr 2015;102:1381-8.